The company's product portfolio includes aesthetic device platforms such as Venus Versa, Venus Legacy, Venus Velocity, Venus Viva, Venus Bliss, and AI.ME, along with hair restoration systems including NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Key recent developments include FDA 510(k) clearance for Venus NOVA, its next-generation multi-application platform, received in November 2025.
Cyborg Score Rationale
Venus Concept faces significant financial headwinds with Q3 2025 revenue of $13.8M (down 8% year-over-year) and a GAAP net loss of $22.5M with Adjusted EBITDA loss of $7.8M, offset by strong product innovation and private capital backing. The company's transition to private ownership provides strategic flexibility but reflects market challenges.
Top Insights
Company transitioned to private ownership via Madryn-controlled short-form merger effective March 30, 2026, delisting from NASDAQ.
Revenue declining (down 8% YoY in Q3 2025) with gross margin compression due to U.S. tariffs and lower volumes.
FDA 510(k) clearance for Venus NOVA (November 2025) and debt-to-equity exchanges totaling $18M in 2025 reflect active capital restructuring.
Planned sale of Venus Hair Business to MHG remains delayed with company seeking Delaware Court of Chancery assistance.
Named Competitors
Cutera — Laser and energy-based aesthetic devices
Candela Medical — Aesthetic and surgical laser systems